What Is Bio-Rad Laboratories, Inc. (BIO) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Bio-Rad Laboratories, Inc.'s intrinsic value is estimated at $264.17. Trading at its current price of $297.56, the valuation engine raises significant caution: 10 of 13 models flag downside risk, projecting an average implied return of -11.2%. Model dispersion is worth noting: Regime Cross targets $1,492.76 (+401.7%), versus Markov DDM at $64.40 (-78.4%). This +480.0% range highlights the importance of multi-model analysis rather than relying on any single methodology. Among models with highest confidence, EPV lean bearish — adding weight to the bearish side of the thesis.
What Do the Models Say About BIO?
13 of 13 models are currently active for BIO. Of these, 3 models suggest upside while 10 models suggest overvaluation. The Bayesian DCF estimates BIO's intrinsic value at $163.04, implying -45.2% downside from the current price. See which stocks rank higher →
How Does BIO Rank in Laboratory Analytical Instruments?
Among 21 Laboratory Analytical Instruments stocks, BIO ranks #5 by Quality of Company score. CirclFi's QOC score of 8.1/10 evaluates 32 fundamental signals. A score of 8.1 places BIO in the top tier.
Bio-Rad Laboratories, Inc. operates in a competitive landscape where fundamental quality metrics are key differentiators for long-term value creation.
Is BIO a Value Trap?
The Value Trap algorithm is not active for BIO. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
13 of 13 models are active for Bio-Rad Laboratories, Inc.. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Quality of Company (QOC) framework, Bio-Rad Laboratories, Inc. earns a quality score of 8.1/10. This robust rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency.
The gap between the most bullish and bearish model spans +480.0% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every BIO valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across BIO's 13 active models, average confidence is 47%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad